RPL36AP17: A Promising Drug Target / Biomarker (G100271326)

Target Name: RPL36AP17

NCBI ID: G100271326

RPL36AP17

Other Name(s): RPL36A_4_361 | ribosomal protein L36a pseudogene 17 | Ribosomal protein L36a pseudogene 17

RPL36AP17: A Promising Drug Target / Biomarker

RPL36AP17 is a gene that encodes a protein known as RPL36AP17. RPL36AP17 is a member of the RPL36 family of proteins, which are involved in the regulation of mitochondrial dynamics. The RPL36 family plays a crucial role in the regulation of various cellular processes, including cell growth, apoptosis, and metabolism. RPL36AP17 is specifically involved in the regulation of mitochondrial translation, which is the process by which proteins are synthesized from mRNA in the mitochondria.

The RPL36AP17 gene has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. In this article, we will discuss the potential mechanisms by which RPL36AP17 can be targeted or used as a biomarker for these diseases, as well as any current research efforts aimed at understanding its role in these conditions.

Potential Drug Target

One of the primary functions of RPL36AP17 is the regulation of mitochondrial translation. Mitochondria are organelles that are responsible for generating the majority of the energy for cellular metabolism. They are also involved in the regulation of various cellular processes, including apoptosis, autophagy, and inflammation. The regulation of mitochondrial translation is critical for the proper functioning of these organelles, and RPL36AP17 plays a key role in this process.

Studies have suggested that RPL36AP17 may be a potential drug target for various diseases, including cancer. In cancer, the regulation of mitochondrial translation is often disrupted, leading to an increase in the production of misfolded proteins. These misfolded proteins can cause a variety of cellular problems, including the formation of aggregates, the inhibition of cellular signaling pathways, and the disruption of cellular homeostasis.

In addition to its role in the regulation of mitochondrial translation, RPL36AP17 has also been shown to be involved in the regulation of cell apoptosis. Apoptosis is a natural process that is involved in the regulation of cellular life and death. It is often triggered by various factors, including the exposure of cells to stressors or mutations. The regulation of apoptosis is critical for the proper functioning of cells, and RPL36AP17 plays a key role in this process.

Potential Biomarker

In addition to its potential as a drug target, RPL36AP17 has also been identified as a potential biomarker for various diseases. One of the primary functions of RPL36AP17 is the regulation of mitochondrial translation, which is the process by which proteins are synthesized from mRNA in the mitochondria. This is important for the production of a wide variety of cellular proteins, including enzymes, signaling proteins, and structural proteins.

The regulation of mitochondrial translation is often disrupted in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The production of misfolded proteins in these conditions can cause a variety of cellular problems, including the formation of aggregates, the inhibition of cellular signaling pathways, and the disruption of cellular homeostasis.

RPL36AP17 has been shown to be involved in the regulation of mitochondrial translation in various conditions. For example, studies have suggested that RPL36AP17 is involved in the regulation of the translation of the protein parkin, which is involved in the production of reactive oxygen species (ROS). RPL36AP17 has also been shown to be involved in the regulation of the translation of the protein AP-1, which is involved in the production of insulin-like growth factor 1 (IGF-1).

In addition to its role in the regulation of mitochondrial translation, RPL36AP17 has also been shown to be involved in

Protein Name: Ribosomal Protein L36a Pseudogene 17

The "RPL36AP17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36AP17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets